AbbVie reduced its full-year adjusted EPS guidance by $0.14 per share due to the Apogee acquisition, falling below Wall Street expectations.
AbbVie lowered its 2026 adjusted earnings per share guidance after accounting for a $0.14 per-share impact from its proposed $10.9 billion Apogee acquisition. The revision places the company’s outlook below Wall Street estimates, signaling potential headwinds from the deal’s integration costs or financing impacts.
Prior guidance had not factored in the acquisition, which was announced earlier this year. Analysts had anticipated a more modest adjustment, but the $0.14 reduction reflects higher-than-expected near-term dilution or operational challenges. The company’s shares may face pressure as investors reassess growth projections.
T. Rowe Price outperformed expectations, while Moderna’s shares dropped over 7% after its norovirus vaccine trial failed to meet early success criteria despite strong quarterly results.